When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Turning Point Therapeutics (TPTX+1.9%) announces encouraging results from preclinical studies evaluating lead drug repotrectinib, a tyrosine kinase inhibitor. Results showed that the combination of repotrectinib and proxy molecules for Amgen's AMG510 or Novartis' Mekinist (trametinib) showed a synergistic effect over the single agent by reducing tumor cell growth and enhancing tumor cell death. The combo studies were replicated across panels of KRAS-positive non-small cell lung, colorectal and pancreatic cancer cell lines.
More news on: Turning Point Therapeutics, Inc., Healthcare stocks news,